CohBar announced that it has initiated a Phase 1a/1b safety and biomarker study of CB4211, its lead MBT candidate under development as a potential treatment for non-alcoholic steatohepatitis, or NASH, and obesity. CB4211 is the first mitochondria based therapeutic to enter clinical testing.
CohBar announced the presentation of preclinical data on CB4211, its lead mitochondria based therapeutics candidate under development as a potential treatment for non-alcoholic steatohepatitis, at the American Diabetes Association 78th Scientific Sessions, held June 22-26. "The in vitro evidence for CB4211 acting as an insulin sensitizer is consistent with our prior preclinical observations in vivo...We believe CB4211 affects a foundational event in the etiology of NASH and potentially other metabolic diseases. The novel mechanism of action of CB4211 may also offer a complementary approach to other mechanisms currently being explored for the treatment of NASH and other metabolic diseases. We look forward to further testing the potential of CB4211 in clinical studies," said CohBar's Chief Scientific Officer Kenneth Cundy.